News

Sovaldi’s high price limits drug access


 

References

The high cost of the hepatitis C treatment Sovaldi has caused a steep increase in Medicaid spending, though access to the drug remains extremely limited for low-income patients, reports the Wall Street Journal’s Joseph Walker in an analysis of federal data.

The drug, manufactured by Gilead Sciences, comes at a cost of $84,000 for the course of treatment, or $1,000 per pill.

State Medicaid programs spent $1.08 billion on Sovaldi alone and $1.33 billion on all HCV treatments in the first 9 months of 2014, according to the analysis. As a result, states have started to limit access to only the most severe HCV cases, sparking tension among physicians, patients, and state officials.

Though competition between Sovaldi and AbbVie’s Viekira Pak would allow states to negotiate greater discounts and expand coverage, most states continue to deny access to all but the sickest eligible patients, according to the report.Read the full Wall Street Journal article here.

Recommended Reading

Study found two-way link between IBD and cervical cancer
MDedge Internal Medicine
Two-thirds of endoscopists met colonic adenoma detection benchmarks
MDedge Internal Medicine
Four genes linked to phenotypic traits of Crohn’s disease
MDedge Internal Medicine
All-oral simeprevir-sofosbuvir beat interferon-based regimen for HCV with compensated cirrhosis
MDedge Internal Medicine
New hepatitis treatment cost effective for some patient types
MDedge Internal Medicine
Add baseline DHEAS when screening adrenal incidentalomas for subclinical hypercortisolism
MDedge Internal Medicine
United States experiencing drug-resistant shigellosis outbreak
MDedge Internal Medicine
No increased risk of lung disease with methotrexate
MDedge Internal Medicine
Antihistamine drug chlorcyclizine shows promise for treating HCV
MDedge Internal Medicine
Stem cells may provide long-term relief from Crohn’s fistula
MDedge Internal Medicine